Introduction to the use of belatacept: A fusion protein for the prevention of post transplant kidney rejection

Giovanbattista Ippoliti, Andrea Maria D'Armini, Marco Lucioni, Mazen Marjieh, Mario Viganò

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preventing CD28 activation and by binding its ligands B7-1 and B7-2. The result is an inactivation of costimulatory pathways. A comparative analysis of the BENEFIT and BENEFIT-EXT datasets showed belatacept regimens resulted in better cardiovascular and metabolic risk profiles than did cyclosporin A (CsA) regimens: belatacept likewise outperformed CsA in terms of lower blood pressure and serum lipids and less new onset diabetes after transplantation. About 20% of belatacept-treated patients developed adverse effects which included anemia, pyrexia, neutropenia, diarrhea, urinary tract infection, headache, and peripheral edema. At present, belatacept does not seem to predispose patients to a higher rate of infection than CsA maintenance immunosuppression. The risk of posttransplant lymphoproliferative diseases was higher in Epstein-Barr virus (EBV)-seronegative patients than in EBV-seropositive patients, but the risk may be reduced by use of a less intensive regimen and avoidance of EBV-negative patients and of patients whose pretransplant EBV serology is unknown. Belatacept provides a new option for immunosuppressive therapy in kidney transplantation, but needs further evaluation in terms of the late effects that may derive from prolonged blockage of the costimulatory system and the induction of tolerance status.

Original languageEnglish
Pages (from-to)355-362
Number of pages8
JournalBiologics: Targets and Therapy
Volume6
DOIs
Publication statusPublished - Oct 3 2012

Fingerprint

Graft Rejection
Human Herpesvirus 4
Kidney
Immunosuppressive Agents
Cyclosporine
Proteins
Kidney Transplantation
CD80 Antigens
Metabolome
Serology
Neutropenia
Urinary Tract Infections
Pharmaceutical Preparations
Immunosuppression
Headache
Abatacept
Anemia
Diarrhea
Edema
Fever

Keywords

  • Belatacept
  • Costimulation
  • Organ transplantation

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Introduction to the use of belatacept : A fusion protein for the prevention of post transplant kidney rejection. / Ippoliti, Giovanbattista; D'Armini, Andrea Maria; Lucioni, Marco; Marjieh, Mazen; Viganò, Mario.

In: Biologics: Targets and Therapy, Vol. 6, 03.10.2012, p. 355-362.

Research output: Contribution to journalArticle

@article{7ba7b7c7fb22422894c8e513f8a3937e,
title = "Introduction to the use of belatacept: A fusion protein for the prevention of post transplant kidney rejection",
abstract = "The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preventing CD28 activation and by binding its ligands B7-1 and B7-2. The result is an inactivation of costimulatory pathways. A comparative analysis of the BENEFIT and BENEFIT-EXT datasets showed belatacept regimens resulted in better cardiovascular and metabolic risk profiles than did cyclosporin A (CsA) regimens: belatacept likewise outperformed CsA in terms of lower blood pressure and serum lipids and less new onset diabetes after transplantation. About 20{\%} of belatacept-treated patients developed adverse effects which included anemia, pyrexia, neutropenia, diarrhea, urinary tract infection, headache, and peripheral edema. At present, belatacept does not seem to predispose patients to a higher rate of infection than CsA maintenance immunosuppression. The risk of posttransplant lymphoproliferative diseases was higher in Epstein-Barr virus (EBV)-seronegative patients than in EBV-seropositive patients, but the risk may be reduced by use of a less intensive regimen and avoidance of EBV-negative patients and of patients whose pretransplant EBV serology is unknown. Belatacept provides a new option for immunosuppressive therapy in kidney transplantation, but needs further evaluation in terms of the late effects that may derive from prolonged blockage of the costimulatory system and the induction of tolerance status.",
keywords = "Belatacept, Costimulation, Organ transplantation",
author = "Giovanbattista Ippoliti and D'Armini, {Andrea Maria} and Marco Lucioni and Mazen Marjieh and Mario Vigan{\`o}",
year = "2012",
month = "10",
day = "3",
doi = "10.2147/BTT.S27565",
language = "English",
volume = "6",
pages = "355--362",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Introduction to the use of belatacept

T2 - A fusion protein for the prevention of post transplant kidney rejection

AU - Ippoliti, Giovanbattista

AU - D'Armini, Andrea Maria

AU - Lucioni, Marco

AU - Marjieh, Mazen

AU - Viganò, Mario

PY - 2012/10/3

Y1 - 2012/10/3

N2 - The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preventing CD28 activation and by binding its ligands B7-1 and B7-2. The result is an inactivation of costimulatory pathways. A comparative analysis of the BENEFIT and BENEFIT-EXT datasets showed belatacept regimens resulted in better cardiovascular and metabolic risk profiles than did cyclosporin A (CsA) regimens: belatacept likewise outperformed CsA in terms of lower blood pressure and serum lipids and less new onset diabetes after transplantation. About 20% of belatacept-treated patients developed adverse effects which included anemia, pyrexia, neutropenia, diarrhea, urinary tract infection, headache, and peripheral edema. At present, belatacept does not seem to predispose patients to a higher rate of infection than CsA maintenance immunosuppression. The risk of posttransplant lymphoproliferative diseases was higher in Epstein-Barr virus (EBV)-seronegative patients than in EBV-seropositive patients, but the risk may be reduced by use of a less intensive regimen and avoidance of EBV-negative patients and of patients whose pretransplant EBV serology is unknown. Belatacept provides a new option for immunosuppressive therapy in kidney transplantation, but needs further evaluation in terms of the late effects that may derive from prolonged blockage of the costimulatory system and the induction of tolerance status.

AB - The development of new immunosuppressive drugs for kidney transplantation resulted both in better short-term outcomes and in decreased metabolic, cardiovascular, and nephrotoxicity risk. Belatacept belongs to a new class of immunosuppressive drugs that selectively inhibits T-cell activation by preventing CD28 activation and by binding its ligands B7-1 and B7-2. The result is an inactivation of costimulatory pathways. A comparative analysis of the BENEFIT and BENEFIT-EXT datasets showed belatacept regimens resulted in better cardiovascular and metabolic risk profiles than did cyclosporin A (CsA) regimens: belatacept likewise outperformed CsA in terms of lower blood pressure and serum lipids and less new onset diabetes after transplantation. About 20% of belatacept-treated patients developed adverse effects which included anemia, pyrexia, neutropenia, diarrhea, urinary tract infection, headache, and peripheral edema. At present, belatacept does not seem to predispose patients to a higher rate of infection than CsA maintenance immunosuppression. The risk of posttransplant lymphoproliferative diseases was higher in Epstein-Barr virus (EBV)-seronegative patients than in EBV-seropositive patients, but the risk may be reduced by use of a less intensive regimen and avoidance of EBV-negative patients and of patients whose pretransplant EBV serology is unknown. Belatacept provides a new option for immunosuppressive therapy in kidney transplantation, but needs further evaluation in terms of the late effects that may derive from prolonged blockage of the costimulatory system and the induction of tolerance status.

KW - Belatacept

KW - Costimulation

KW - Organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=84872259157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872259157&partnerID=8YFLogxK

U2 - 10.2147/BTT.S27565

DO - 10.2147/BTT.S27565

M3 - Article

C2 - 23055693

AN - SCOPUS:84872259157

VL - 6

SP - 355

EP - 362

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

ER -